Beta-blocker therapy after acute coronary syndrome in patients without heart failure or reduced ejection fraction: A target-trial emulation study
Clicks: 9
ID: 321847
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
2.4
/100
9 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #59 of 194 articles by views in european journal of preventive cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AIMS: The benefits of β-blockers in patients with acute coronary syndromes (ACS) without chronic heart failure (HF) or left ventricular ejection fraction (LVEF) < 40% remain uncertain. We evaluated the association between β-blocker therapy and clinical outcomes in a multicenter, contemporary ACS registry. METHODS: In the START-ANTIPLATELET registry (NCT02219984), patients were excluded if they had HF or LVEF <40%. Participants were stratified according to β-blocker use at discharge after ACS. A target trial emulation and inverse probability of treatment weighting (IPTW) were used. The primary endpoint was a composite of all-cause death or myocardial infarction (MI) at 1 year. RESULTS: The primary analysis included 1,315 patients with ACS without HF or LVEF <40%, of whom 949 (72.2%) were discharged on β-blockers. At 1 year, the primary endpoint occurred in 21 (2.2%) patients receiving β-blockers versus 13 (3.6%) without β-blockers, and no significant association was observed (unweighted HR 0.63, 95% CI 0.31-1.26; p = 0.192; IPTW-adjusted HR 0.66, 95% CI 0.33-1.33; p = 0.249). Exploratory subgroup analyses suggested a potentially more favourable association of β-blocker therapy in patients with ST-segment elevation MI (p-interaction=0.049), although this finding was not uniformly reproduced across sensitivity analyses. CONCLUSIONS: In a contemporary real-world cohort of ACS patients without HF or LVEF <40%, β-blocker therapy was prescribed in approximately 70% of patients and was not associated with a lower 1-year risk of death or MI.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (56 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7170084204
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | V De Sio, Felice Gragnano, Arturo Cesaro, M Galli, E Moscarella, M Berteotti, A Capolongo, F Pelliccia, G Verde, Pierre Sabouret, Vincenzo Acerbo, M Luciani, G Cappiello, Dobromir Dobrev, Francesco Perone, Giuseppe Patti, E Antonucci, Pasquale Pignatelli, Vittorio Pengo, Paolo Gresele, P Cirillo, Rossella Marcucci, Paolo Calabrò |
| Journal | european journal of preventive cardiology |
| Year | 2026 |
| DOI |
10.1093/eurjpc/zwag381
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.